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Appropriate Management      
of Adult Migraines 
Dane Shiltz, PharmD, BCPS 
Clinical Pharmacy Specialist, Methodist Hospital 
Assistant Professor, Butler University COPHS 
 
Friday, June 1, 2012 
• I have nothing to disclose. 
Disclosure Statement 
• Recognize migraine headache & common 
symptoms 
 
• Identify acute treatment options 
 
• Identify migraine prophylaxis agents 
 
• Describe potential drug interactions & side 
effects associated with abortive & 
prophylactic therapies 
Objectives 
• A primary headache (HA) disorder 
 
• Onset 5-11 (males), 12-17 (females) 
 
• Peak prevalence 30-49 
 
• Females >> males 
 
• Common comorbidities – causal relationship? 
– Depression, anxiety, stroke, epilepsy 
Migraine Facts 
• First or worst episode ever 
 
• Onset >50 years 
 
• Secondary to systemic illness 
– Fever, N/V, stiff neck, rash 
 
• Focal neurologic symptoms 
 
• New onset in a patient with HIV or cancer 
Non-Migraine Warnings 
• 2 subtypes: with & without aura 
 
• 63% experience 1-4 attacks/month 
 
• Gradual onset, typically unilateral throbbing or 
pulsatile pain usually in frontotemporal region 
– Duration 4-72 hours untreated 
 
• N/V, phonophobia, photophobia variable 
 
• ↓ concentration, depression, anxiety, fatigue 
Presentation 
• Initiating factors unknown 
– Environment, diet, medication triggers 
 
• Possible serotonin (5-HT) imbalance 
within brainstem 
– Mg, K, dopamine, glutamate involved 
 
• Genetic role 
 
• Migraine episode ≠ Migraine diagnosis 
Etiology 
• Physical exertion 
 
• Menstruation 
 
• Glare or flickering lights 
 
• Loud noises 
 
• Strong smells & fumes 
 
• Tobacco smoke 
 
• Sleep extremes 
• Dietary triggers 
– Caffeine & caffeine 
withdrawal 
– Dairy products 
– Aspartame 
– Monosodium 
glutamate (MSG) 
– Chocolate 
– Tyramines 
– EtOH 
Triggers 
• Benzodiazepine 
withdrawal 
 
• Estrogens 
– Contraceptives 
– Hormone therapy 
 
• Theophylline 
 
• Cimetidine 
• Indomethacin 
 
• Nitrates 
 
• Nifedipine 
 
• Medication overuse 
– Analgesics 
– Decongestants 
– Ergotamine 
Drug-Induced 
Pathophysiology 
Trigeminovascular afferent activity 
• Brain stem 5-HT neuron imbalance 
Neuropeptide release in dura mater, 
other intracranial extracerebral vessels 
• Neurokinin A, Substance P, CGRP 
Vasodilation, plasma extravasation 
Perivascular inflammation 
Trigeminal nucleus 
caudalis 
Cerebral Cortex 
Phonophobia, 
photophobia 
PAIN 
Pathophysiology 
• Independent of aura/no aura subtypes 
• 20-60% prevalence 
• 1-24 hours prior to migraine onset 
• High inter-, low intra-patient variability 
Phonophobia 
Photophobia 
Hyperosmia 
Difficulty concentrating 
Premonitory Symptoms 
5 Key Features 
• Pulsatile quality 
• One-day duration (range 4-72 hours) 
• Unilateral location 
• Nausea or vomiting 
• Disabling intensity 
 
• Nausea, photophobia, disability 
3/5 criteria = migraine likely      
≥4/5 criteria = migraine highly likely 
2/3 criteria = migraine highly likely 
Diagnosis - No Aura 
• Neurologic sx ≤ 1 hour of or during migraine 
– Onset at start or during attack; fully reversible 
 
• Vision: blindness, flickering lights, spots 
• Sensory: numbness, paresthesias 
• Motor: hemiparesis, weakness 
• Speech: dysphasia 
 
• Duration ≤ 1 hour 
Diagnosis - Aura 
• Which of the following is FALSE? 
 
A.) ~20% patients report dietary migraine triggers 
 
B.) Migraine pain occurs unilaterally 
 
C.) Migraines have a sudden, acute onset 
 
D.) Migraine pain is usually moderate-severe pain 
 
E.) Premonitory symptoms are independent of aura 
Active Learning #1 
Acute Migraine Treatment 
Which of the following is a treatment 
goal for acute migraine 
management? 
 
A.) Provide rapid, consistent, complete relief 
 
B.) Select cost-effective treatment  
 
C.) Prevent or minimize treatment-induced side 
effects 
 
D.) Restore function capacity 
 
E.) All of the above 
Active Learning #2 
• Provide consistent, rapid, complete relief 
 
• Prevent or minimize treatment side effects 
 
• Utilize a tolerated administration route 
 
• Employ a cost-effective acute treatment 
 
• Restore functional capacity 
 
• Prevent recurrences & minimize need for 
escalating abortive doses or other agents 
Treatment Goals 
• Ice packs to head 
 
• Rest – dark, quiet settings 
 
• Identify & avoid triggers 
– Environment, foods, medications 
 
• Headache diary 
– Reveal triggers, frequency, severity, duration 
 
• Relaxation therapy 
Non-Drug Therapy 
• Most effective given within 1st hour of onset 
– Shortens duration & severity 
– Reduces additional doses or other acute agents 
 
• Non-specific agents  mild-moderate attacks 
• Migraine-specific agents  moderate-severe 
 
• Caution oral route 
– N/V, gastroparesis common – reduce absorption 
– Intranasal, PR, ODT, injection route if severe N/V 
Abortive Drug Therapy 

• 1st line nonspecific tx for 
mild to moderate pain 
 
• Inexpensive 
 
• Well tolerated 
 
• Inhibit prostaglandin 
production in 
trigeminovascular  
system 
• Acetaminophen (APAP) 
– 1,000mg q4-6h PRN 
 
• OTC NSAIDs 
– Ibuprofen 200-800mg 
q6h PRN (max 2.4g/day) 
– Naproxen 550mg q4-6h 
PRN (max 1.375g/day) 
– Diclofenac 50mg q8h 
PRN (max 150mg/day) 
Analgesics & NSAIDs 
• Evidence for acetaminophen monotherapy 
limited  often not used alone 
• Limited or inconsistent evidence for benefit 
among other NSAIDs 
• No comparisons between NSAID classes 
• NSAID-induced side effects limit use 
– GI: dyspepsia, N/V, diarrhea 
– CNS: somnolence, dizziness 
Analgesic Points 
• Acetaminophen 250mg/ aspirin 250mg/ 
caffeine 65mg (Excedrin Migraine®) 
– 2 tablets at onset, then q6h PRN 
– Faster onset, better pain relief vs.       
ibuprofen 400mg in one single-dose 
– Caution multi-source APAP intake 
 
• Metoclopramide (Reglan®) can enhance 
analgesic absorption & reduce N/V 
Combinations 
• Acute migraine & treatment-induced N/V 
 
• 15-30 minutes prior to PO abortive therapy 
 
 
 
 
 
 
 
 
• Drowsiness, dizziness 
 
• Monitor for extrapyramidal symptoms 
Antiemetics 
Antiemetic IV/IM Dose PR Dose 
Metoclopramide 10mg x 1 N/A 
Prochlorperazine 10mg x 1 25mg x 1 
Chlorpromazine 12.5mg x 1 25mg x 1 
• Given during acute attack, often in ER 
 
• 10-24mg IV one-time dose to prevent 
migraine recurrence for 72 hours 
– Reduces recurrent episodes 26% 
 
• No effect on acute pain reduction! 
– Adjunct to abortive therapies 
Dexamethasone 
Nonspecific Treatment Algorithm 
Acetaminophen (APAP) 
OTC NSAID APAP/ASA/caffeine 
RX (strength) NSAID: ibuprofen, ketoprofen 
or specific migraine therapy 
Summary 
• 5-HT1B/1D Agonists 
1.) Vasoconstrict intracranial vessels 
2.) Inhibit vasoactive neuropeptide release 
3.) Interrupt pain signal transmission at brain stem 
 
• 1st line for moderate to severe pain 
– Rescue therapy if nonspecific drugs ineffective 
– Most effective, least nauseating specific therapy 
Triptans 
• Sumatriptan (Imitrex®) 
 
• Zolmitriptan (Zomig®) 
• Rizatriptan (Maxalt®) 
• Almotriptan (Axert®) 
• Eletriptan (Relpax®) 
• Naratriptan (Naramig®) 
• Frovatriptan (Frova®) 
• 2nd generation triptans 
– Better bioavailability 
– Longer t1/2 
Triptan Products 
Triptan Onset of Action Elimination t1/2 
Sumatriptan Tablet: 30-60 min 
Nasal: 10-15 min 
SubQ: 10 min 
2 hrs 
Zolmitriptan Tablet: 30-60 min 
Nasal: 10-15 min 
2-3 hrs 
Rizatriptan 30-60 min 2-3 hrs 
Almotriptan 30-60 min 3-4 hrs 
Eletriptan 30-60 min 3-4 hrs 
Naratriptan 1-3 hrs 6 hrs 
Frovatriptan 2 hrs 25 hrs 
Oral Route Initial Dose Rpt 
Time 
Max Dose/Day 
Sumatriptan 25-100mg 2 hrs 200mg 
Zolmitriptan 1.25-2.5mg 2 hrs 10mg 
Rizatriptan 
     Propranolol 
5-10mg 2 hrs 30mg 
5mg 2 hrs 15mg 
Almotriptan 
       CrCl < 30 
6.25-12.5mg 2 hrs 25mg 
≤ 6.25mg 2 hrs 12.5mg 
Eletriptan 20-40mg 2 hrs 80mg 
Naratriptan 
     CrCl 15-39 
1-2.5mg 
1mg 
4 hrs 
4 hrs 
5mg 
2.5mg 
Frovatriptan 2.5mg 2 hrs 7.5mg 
Initial Dose Route Rpt 
Time 
Max Daily 
Dose 
Sumatriptan 
 
5,10,20mg Nasal 2 hrs 40mg 
6mg SubQ 1 hr 12mg 
Zolmitriptan 5mg Nasal 2 hrs 10mg 
2.5mg ODT 2 hrs 10mg 
Rizatriptan 5,10mg ODT 2 hrs 40mg 
Alternative Routes 
• Treximet® 
• Sumatriptan 85mg + naproxen 500mg 
• No benefit in severe migraine vs. 
sumatriptan or naproxen alone 
– 2-hour headache relief, 2-24 hr recurrence 
rates similar 
• Potential benefit in moderate migraine 
• Cost $$ 
Sumatriptan + Naproxen 
• Cost $$ 
 
• Avoid x 14 days after 
monoamine oxidase 
inhibitor (MAOI) use 
– Sumatriptan, 
rizatriptan, zolmitriptan 
 
• Caution concomitant 
SSRI & TCA use 
– Serotonin syndrome 
• “Catch” the pain early! 
 
• No class effect! 
 
• Response (~60%)  
recurrence ≠ failure 
 
• Side effects 
– Paresthesias 
– Flushing 
– Nausea 
Triptan Pearls 
SSRIs, TCAs 
(-) 
5-HT Receptors 
Post-synaptic 
Neuron 
Pre-synaptic Neuron 
5-HT 
Vesicle 
5-HT Reuptake 
Transporter 
• Noncardiac chest sxs 
– ~15% incidence 
– Tightness, pressure, 
heaviness or pain in 
chest, neck, throat 
 
 
• Partial 5-HT coronary 
vessel agonists 
– Coronary vasoconstriction 
 
• Contraindications 
– Chronic stable angina 
– Myocardial infarction 
– Prinzmetal’s angina 
– Uncontrolled HTN 
– TIA/CVA history 
 
• Assess those with 
cardiovascular risk 
factors prior to use 
Triptans & CV Disease 
• Nonselective 5-HT, α1 
agonists 
 
• Constrict intracranial 
vessels & inhibit 
trigeminovascular 
system inflammation 
 
• Constrict venous & 
arterial vessels 
 
• Do not use within 24 
hours of triptan use 
• Contraindications 
– Renal or hepatic failure 
– CAD, CVA/TIA, PVD 
– Uncontrolled HTN 
– Pregnancy & nursing 
– CYP 3A4 inhibitors 
– Use ≤2 weeks of MAOI 
 
2nd line agents:                       
1) triptans intolerable   
and/or ineffective                              
2) high recurrence risk         
3) duration >48 hours 
Ergot Alkaloids 
• Ergotamine ±caffeine more nauseating vs. 
dihydroergotamine (DHE) 
 
 
• Pretreat with antiemetic for all ergotamine routes 
 
 
• Side effects – N/V, pruritis, hypertension 
– Possible cardiac valve fibrosis with long-term use 
 
 
• Medication overuse HA  follow dose limits 
 
 
• More potent vasoconstrictor vs. DHE 
Ergotamine Notes 
• Ergotamine without caffeine (Ergomar®) 
 
 
• Do not crush or chew tablets 
 
 
• Sublingual 2mg tablet 
 
 
• 1 tablet at onset, then 1 tablet q30min PRN 
– Max 3 tablets/24 hours; 5 tablets/week 
 
Sublingual Route 
Tablet - Cafergot® 
• Ergotamine 1mg / caffeine 100mg 
• 2 tablets PO at onset, then 1 tablet q30min PRN 
– Max 6 tablets/attack; 10 tablets/week 
 
Suppository - Migergot® 
• Ergotamine 2mg / caffeine 100mg 
• 1 suppository PR at onset, then 1 additional dose 
after 1 hour PRN 
– Max 2 suppositories/attack; 5 suppositories/week 
Ergotamine + Caffeine 
• High doses, drug interactions, extended use 
 
• Peripheral ischemic symptoms 
– cold, numb, peripheral extremities 
– reduced or absent peripheral pulses 
– gangrenous skin, bowel ischemia, MI 
 
• Convulsive symptoms 
– seizures, muscle spasms 
– mania, psychosis, hallucinations 
 
Ergotism 

Ergotamine Literature 
• Most early ergotamine trials used no comparison 
 
• Most International Headache Society (IHS) migraine 
diagnostic criteria not used 
 
• Data on attack frequency reduction at 2 hour mark 
not available for any trials 
 
• Inconsistent efficacy vs. placebo (50/50) 
 
• Inconsistent effect on reducing abortive use 
 
• N/V more severe ergotamine±caffeine >> placebo 
 
• Ergotamine±caffeine more preferred vs. placebo 
Dihydroergotamine (DHE) 
• Nasal (Migranal®), IV, IM, SQ (D.H.E. 45®) 
• Not linked with medication overuse HA 
• Pretreat with antiemetic prior to IV use 
• 1mg at onset IV/IM/SQ, then q1hr PRN 
– Max 3mg/day or 6mg/week 
• 1 spray (0.5mg) in each nostril x 1, may repeat 
sequence q15min PRN up to total 2mg (4 sprays) 
– Max dose 3mg (6 sprays)/24 hours 
– Rhinitis (~25%) most common side effect 
DHE Notes 
• IV routes used in ER 
 
 
• Parenteral DHE works better than ergotamine 
– Also less N/V vs. ergotamine with non-IV route 
 
 
• DHE effective late in migraine episode when 
triptans ineffective 
– Slower onset, but longer lasting vs. triptans 
Agent Route Bioavailability 
Ergotamine (PO) <1% 
SL <1% 
PR 1-3% 
DHE Nasal 40% 
IM 100% 
IV 100% 
Kinetics 
• Morphine, fentanyl, hydromorphone 
– Usually IV/IM route in ED 
– Sedation, N/V, pruritis, depressed respiration 
 
 
• Moderate to severe pain 
– Contraindications to other acute treatment 
– Rescue therapy if no relief with conventional 
abortive treatment or poorly tolerated 
 
 
• Dependency, medication overuse potential 
Opioids 
• Stadol® nasal spray 
 
• Mixed opioid 
agonist-antagonist 
 
• 1 spray (1mg) in 1 
nostril at onset 
 
• Repeat q1hr PRN  
– Max 4 sprays/day 
• Alternative to 
prevent injection use 
in MD office or ED 
 
• High risk for overuse 
& dependence 
– Last line option 
Butorphanol 
Summary of Abortive 
Treatment Efficacy 
2-Hour 
Relief 
24-Hour Sustained 
Pain-Free 
Placebo ~30% ~7% 
APAP (x1) ~58% ? 
NSAID ~43% ~10% 
ASA (x2) ~53% ? 
APAP/ASA/caffeine (x1) ~63% ? 
Triptan ~60% ~20% 
Triptan + NSAID (x1) ~61% ~23% 
Ergotamine ~50% ? 
Abortive Treatment Algorithm 
Acetaminophen, NSAIDs, Combination 
Triptans 
Ergot Alkaloids 
Rescue 
Opioids 
Acute Summary 
• Due to acute treatment use  
>2-3 days/week 
 
 
• Atypical daily or near-daily HA 
with episodic migraines 
 
 
• Causes: simple & combination 
analgesics & opioids, 
ergotamine; triptans less likely 
 
 
• Must discontinue use 
 
 
• 3-12 weeks to reestablish 
baseline response 
Shortened 
Duration of Effect 
Recurrent 
HA 
More acute relief 
medication use 
Overuse Headache 
Migraine Prophylaxis 
• Reduce attack frequency, severity, duration 
 
• Indications 
– Abortive therapy use >2 days/week 
– Abortive therapy contraindicated, ineffective, intolerable 
– Attacks cause significant disability 
– Patient preference or predictable onset 
 
• Start low, titrate over 1-2 months to effective dose 
 
• Allow 2-3 month trial to assess effectiveness, 
continue at least 6-12 months 
Daily Prophylaxis 
• Preferred 1st line option 
 
• Reduce attacks 50% in up to 80% patients 
 
• Avoid intrinsic sympathomimetic activity 
 
• Selection by comorbidities 
– Benefit: anxiety, hypertension (HTN), chronic 
stable angina, atrial fibrillation, heart failure 
– Caution: Diabetes, asthma, COPD, depression 
β-Blockers 
Migraine 
Prophylactic Dose 
Hypertension 
Treatment Dose 
Timolol* 20-60mg/day (÷) 20-40mg/day (÷) 
Propranolol* 80-240mg/day (÷) 40-160mg/day (÷) 
Metoprolol 50-300mg/day (÷) 50-100mg/day (÷) 
Nadolol 80-240mg/day 40-120mg/day 
Atenolol 25-100mg/day 25-100mg/day 
* FDA-approved for migraine prophylaxis 
Dose Comparisons 
• Depacon® - valproate Na injection 
• Depakene® - valproic acid capsule or liquid 
– BID or TID dosing 
• Dapakote® - divalproex Na capsule 
– Immediate-release (IR) sprinkle capsule 
• BID or TID dosing 
– Delayed-release (DR) capsule 
• BID or TID dosing 
– Extended-release (ER) capsule 
• Daily dosing 
Valproic Acid (VPA)* 
• 1st line option 
– Decrease frequency ≥ 50% in 50% patients 
 
 
• Mechanism 
 1.) Enhance inhibitory GABA actions 
 2.) Reduce excitatory glutamate effects 
 3.) Block Na, Ca channels 
 
 
• 250-750mg BID 
VPA 
• N/V – most common 
 
• Thrombocytopenia 
 
• Tremor, weight gain 
 
• Hepatotoxicity 
– Baseline LFTs & 
frequently within first 6 
months 
– Recheck if sxs or >1 
hepatotoxic drug used 
• Hyperammonemia 
– Only check if lethargy, 
persistent N/V, AMS 
 
• Contraindications 
– Pregnancy 
– Chronic liver disease 
– Pancreatitis history 
 
• Usual therapeutic 
range: 50-100mcg/mL 
VPA Monitoring 
• Decrease VPA concentrations via induction 
– Phenytoin (PHT), carbamazepine (CBZ), 
phenobarbital (PB), rifampin 
• Increase VPA concentrations via inhibition 
– Felbamate 
• Increase VPA clearance – carbapenems 
– VPA dose increase no help; avoid meropenem 
• Increased NH3 & encephalopathy incidence 
– Topiramate 
VPA Interactions 
• 1st line option 
– Decrease frequency ≥ 50% in 50% patients 
 
• Mechanism 
 1.) Enhance inhibitory GABA actions 
 2.) Reduce excitatory glutamate effects 
 3.) Blocks voltage-gated Na channels 
 4.) Inhibits carbonic anhydrase 
 
• Starting dose 25mg/day 
– Increase by 25mg weekly to 50mg BID 
– Total daily target dose 50-200mg 
Topiramate* 
Topamax® 
• Paresthesias (9-23%) 
 
• Anorexia, weight loss 
(16-19%) 
 
• Somnolence (13%) 
 
• Kidney stones (1.5%) 
– Prevent with hydration 
 
• Oligohydrosis (rare) 
• Hyperchloremic non-gap 
metabolic acidosis 
– Dose-related (23-44%) 
– Baseline & periodic HCO3
- 
 
• CrCl ≤ 70 mL/min 
– 50% of normal dose 
 
• Taper therapy to avoid 
risk for seizure 
– ↓ dose 25mg/week 
Topiramate Monitoring 
• Decreased topiramate concentrations 
– Phenytoin (PHT), carbamazepine (CBZ), 
phenobarbital (PB), rifampin, valproic acid (VPA) 
 
• Increased topiramate concentrations 
– HCTZ (combo also increases hypokalemia risk) 
 
• Increased NH3 & encephalopathy incidence 
– VPA 
 
• Decreased Lithium (Li) concentrations 
Topiramate Interactions 
• 1st line option 
 
• Mechanism 
– Nonselective SNRI 
– Down-regulate central 
5-HT2 receptors 
– α1 blocking properties 
 
• Benefit independent of 
antidepressant effect 
 
• 25-150mg HS 
– Titrate weekly as needed 
• Side effects 
– Sedation 
– Anticholinergic 
• S.L.U.D.GE 
– Weight gain 
– Hypotension 
– Cardiac arrhythmias 
– Lower seizure threshold 
 
 
• Avoid in elderly 
– Falls 
– Urine retention 
Amitriptyline 
Elavil® 
• MAOIs – avoid ≥2 weeks after MAOI use 
 
• SSRIs, SNRIs – caution serotonin syndrome 
 
• Increased concentrations via inhibition – VPA 
 
• Decreased concentrations via induction – CBZ 
 
• Anticholinergics – additive effect 
– OABs, diphenhydramine, benztropine 
 
• Increased risk for arrhythmias – quinidine 
Amitriptyline Interactions 
• 2nd line option 
 
• SNRI 
 
• Effexor® IR = BID 
 
• Effexor XR® = Qday 
 
• Starting daily dose 
75mg 
– Increase by 75mg/wk 
– Target daily dose    
150-225mg 
 
Side effects 
• GI intolerance 
– Nausea, dry mouth, 
anorexia, constipation 
• CNS 
– Dizziness, somnolence 
– Insomnia, tremor 
• Sweating 
• Sexual dysfunction 
Venlafaxine 
• MAOIs 
– Wait ≥2 weeks after stopping MAOI to start 
– Wait ≥7 days after stopping venlafaxine to start 
 
 
• SSRIs, TCAs – caution serotonin syndrome 
 
 
• Antihypertensives 
– Venlafaxine can increase DBP ≥10mmHg 
– Dose-dependent 
Venlafaxine Interactions 
• Botulinum toxin A (BoNTA®) 
 
• Acetylcholine receptor antagonist of 
somatic motor neurons 
•   
• Indication: chronic migraine 
– ≥15 headaches/month 
– 155 units over 31 injection sites q3months 
 
• Ineffective for episodic migraine 
 
Botulinum Toxin 
• Intermittently used for menstrual migraines 
– Chronic use limited by GI & nephrotoxicity 
 
• Initiate 1-2 days prior to predictable onset 
 
• Use daily through time of increased risk & 
then discontinue 
 
• Better data for temporary daily prophylactic 
frovatriptan, naratriptan, or zolmitriptan 
NSAIDs 
• Possibly effective 
 
– Lisinopril, candesartan 
 
– Clonidine, guanfacine 
 
– Carbamazepine (CBZ) 
 
– Nebivolol 
 
Emerging Data 
• Conflicting data to support or refute 
– Protryptyline, SSRIs, gabapentin, CCBs 
 
• Possibly not effective 
– Acebutolol, oxcarbazepine (OXZ), telmisartan 
 
• Probably not effective – clomipramine 
 
• Not effective – lamotrigine 
Avoid Use 
ß-Blockers 
Valproic acid Amitriptyline Topiramate 
Venlafaxine Botulinum 
Toxin 
Topiramate + Amitriptyline 
Topiramate + β-blocker    
β-blocker + Valproic acid 
Prophylaxis Algorithm 
Migraine Therapy Pregnancy Category 
Acetaminophen (APAP) B 
NSAIDs B; C/D in 3rd trimester 
APAP/ASA/caffeine C 
Triptans Cŧ 
Ergot alkaloids X 
Butorphanol C 
Beta-blockers Cŧ 
Valproic acid D 
Topiramate C 
Amitriptyline D 
Venlafaxine C 
Botulinum toxin C 
• Individualize abortive & 
prophylactic treatment 
– Response 
– Side effects 
– Contraindications 
– Cost 
– Comorbidities 
 
 
• Analgesics, NSAIDs 
– Mild to moderate attacks 
– Caution overuse risk 
• Triptans, DHE 
– Moderate to severe 
attacks 
– Analgesic/NSAID failure 
 
• Recognize prophylaxis 
indications 
– Routinely assess benefit 
– Consider therapy taper 
& discontinuation during 
prolonged migraine-free 
intervals 
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Antiemetic IV/IM Dose PR Dose 
Metoclopramide 10mg x 1 N/A 
Prochlorperazine 10mg x 1 25mg x 1 
Chlorpromazine 12.5mg x 1 25mg x 1 
Triptan Onset of Action Elimination t1/2 
Sumatriptan Tablet: 30-60 min 
Nasal: 10-15 min 
SubQ: 10 min 
2 hrs 
Zolmitriptan Tablet: 30-60 min 
Nasal: 10-15 min 
2-3 hrs 
Rizatriptan 30-60 min 2-3 hrs 
Almotriptan 30-60 min 3-4 hrs 
Eletriptan 30-60 min 3-4 hrs 
Naratriptan 1-3 hrs 6 hrs 
Frovatriptan 2 hrs 25 hrs 
Oral Route Initial Dose Rpt 
Time 
Max Dose/Day 
Sumatriptan 25-100mg 2 hrs 200mg 
Zolmitriptan 1.25-2.5mg 2 hrs 10mg 
Rizatriptan 
     Propranolol 
5-10mg 2 hrs 30mg 
5mg 2 hrs 15mg 
Almotriptan 
       CrCl < 30 
6.25-12.5mg 2 hrs 25mg 
≤ 6.25mg 2 hrs 12.5mg 
Eletriptan 20-40mg 2 hrs 80mg 
Naratriptan 
     CrCl 15-39 
1-2.5mg 
1mg 
4 hrs 
4 hrs 
5mg 
2.5mg 
Frovatriptan 2.5mg 2 hrs 7.5mg 
Initial Dose Route Rpt 
Time 
Max Daily 
Dose 
Sumatriptan 
 
5,10,20mg Nasal 2 hrs 40mg 
6mg SubQ 1 hr 12mg 
Zolmitriptan 5mg Nasal 2 hrs 10mg 
2.5mg ODT 2 hrs 10mg 
Rizatriptan 5,10mg ODT 2 hrs 40mg 
Alternative Routes 
Summary of Abortive 
Treatment Efficacy 
2-Hour 
Relief 
24-Hour Sustained 
Pain-Free 
Placebo ~30% ~7% 
APAP (x1) ~58% ? 
NSAID ~43% ~10% 
ASA (x2) ~53% ? 
APAP/ASA/caffeine (x1) ~63% ? 
Triptan ~60% ~20% 
Triptan + NSAID (x1) ~61% ~23% 
Ergotamine ~50% ? 
Migraine 
Prophylactic Dose 
Hypertension 
Treatment Dose 
Timolol* 20-60mg/day (÷) 20-40mg/day (÷) 
Propranolol* 80-240mg/day (÷) 40-160mg/day (÷) 
Metoprolol 50-300mg/day (÷) 50-100mg/day (÷) 
Nadolol 80-240mg/day 40-120mg/day 
Atenolol 25-100mg/day 25-100mg/day 
* FDA-approved for migraine prophylaxis 
Dose Comparisons 
Migraine Therapy Pregnancy Category 
Acetaminophen (APAP) B 
NSAIDs B; C/D in 3rd trimester 
APAP/ASA/caffeine C 
Triptans Cŧ 
Ergot alkaloids X 
Butorphanol C 
Beta-blockers Cŧ 
Valproic acid D 
Topiramate C 
Amitriptyline D 
Venlafaxine C 
Botulinum toxin C 
